Factors Affecting the Price of Jaypirca

A summary of the drug's performance in clinical studies.

Clinical Outcomes

In the pivotal BRUIN trial for MCL patients previously treated with a BTK inhibitor, JAYPIRCA demonstrated an overall response rate (ORR) of 50%, with a median duration of response (DOR) of 8.3 months. For CLL/SLL patients previously treated with both a BTK and a BCL-2 inhibitor, the ORR was 72% with a median DOR of 12.2 months. These results supported the drug's accelerated approval, with continued approval potentially contingent upon verification of clinical benefit in confirmatory trials.